Amgen’s Enbrel Targeted as Colorado Panel Works on Payment Cap

Colorado’s prescription drug affordability board members indicated Friday they plan to use Medicare’s negotiated price for the autoimmune treatment Enbrel as a key benchmark for setting a limit on what health plans in the state pay for the medication.

Board members said in their first rulemaking hearing on setting an upper payment limit for Amgen Inc.‘s top-selling drug that they may set a cap that’s at or above Medicare’s annual maximum fair price of roughly $30,000 per patient for 2026. The Medicare negotiated price for Enbrel set under the Inflation Reduction Act drug price program is set to take ...